Under the guidance of immunogenomics, how might combination strategies involving CTLA-4/PD-1 inhibitors and small-molecule agents, next-generation immune checkpoint inhibitors, oncolytic viruses, cellular therapies, and vaccines reshape the therapeutic landscape of melanoma brain metastases? This evidence concerns the gene CTLA4 and melanoma.